Objective: The aim of the study was to investigate the influence of participant expectation on the outcome of a trial that compared two behind-the-ear hearing aids with identical electroacoustic performance, except that one was called a "new" hearing aid and the other a "conventional" hearing aid.
INTRODUCTION
Placebo effects-clinical responses associated with the expectations surrounding treatments rather than with any intrinsic property of the treatment-are wide-ranging and are recognized in medical research and clinical practice (Thompson 2000; Price et al. 2008) . Control conditions for placebo effects are commonly incorporated into clinical trials of medical treatments although these effects are not usually considered in trials of hearing aids. The goal of this study was to examine possible placebo effects in hearing aid trials using experienced adult hearing aid users.
The Placebo Effect
The placebo effect is "a change in a patient's illness attributable to the symbolic import of a treatment rather than a specific pharmacologic or physiologic property of the treatment" (Brody 1980) . Placebo effects have long been recognized, with the first placebo controlled trial conducted in 1801 (de Craen et al. 1999) . Placebo effects currently generate a huge amount of research interest. For example, over the period spanning January to October 2010, about 1650 peer-reviewed publications included the term "placebo" in the title compared with 104 for "hearing aid" based on a Google scholar search. Much of this research is in the area of pain management (Turner et al. 1994) , although general conclusions can be drawn that are likely to be of relevance for hearing aid trials.
First, placebo response rates-the proportion of participants who show placebo responses-are variable but tend to be very high. An early review reported that rates of around 35% were typical (Beecher 1955) , with a more recent review reporting even higher response rates, with an average of 70% (Roberts et al. 1993) . Factors thought to influence the placebo response are discussed below but depend on aspects of the design of the research study, including the nature of the placebo treatment, the characteristics of the clinician, and the clinical environment. Effect sizes vary considerably. Vase et al. (2002) reported a small mean effect size (Cohen's d ϭ 0.15), although effect sizes ranged from Ϫ0.95 to ϩ0.57. Generally, effect sizes were smaller in studies where the placebo was the control condition and larger in studies that examined the placebo mechanism itself. Placebo responses are not just behavioral biases but may also have demonstrable physiological effects. For example, in pain research, placebo-generated analgesic responses are blocked by administration of opioid blockers, suggesting that the placebo response is mediated by endogenous opioid systems (Levene et al. 1978 ). In addition, sham surgery for angina resulted in better exercise tolerance, fewer electrocardiographic abnormalities, and a need for less medication (Dimons et al. 1960) .
The onset of placebo effects may be immediate or delayed and can mimic those of active treatments. For example, the time course of activity of a placebo drug can mimic that of the active treatment (Lasagna et al. 1958) . In a study of Parkinson's disease, a placebo deep brain stimulation procedure resulted in an immediate improvement in motor performance (Pollo 2002) . Placebo effects can also be long lasting, with improvements in the symptoms of angina for up to a year after sham surgery (Dimons et al. 1960) .
In terms of susceptibility to placebo responses, patient characteristics are not good predictors; placebo responses seem to be independent of demographic, intelligence, or other personality factors (Shapiro & Shapiro 1984) , and individual responses tend to vary across trials (Beecher 1955; Liberman 1964) . A range of clinician characteristics has, however, been shown to impact placebo effects. The clinician's warmth, friendliness, empathy, positive attitude, sympathy, and prestige are all associated with greater positive placebo effects (Price et al. 2008) . The clinician's own expectations may also have an effect on outcome. In a study of dental extractions (Gracely et al. 1985) , the placebo response of patients was compared for two groups. In one group, the dentist thought he was administering a narcotic analgesic, a placebo, or a narcotic antagonist. In the second group, the dentist thought he was administering either a placebo or a narcotic antagonist. Although the actual range of possible treatments was the same for both groups of patients, the first group reported significantly less pain. The interpretation was that the dentist's knowledge of the range of possible treatments resulted in subtle changes in behavior that influenced the patient's response.
Placebo responses themselves are highly specific and selective. Bennedetti et al. (1999) injected the irritant capsaicin into the four limbs of study participants. Participants experienced a reduction in pain only for those limbs that had been treated with a placebo analgesic.
Several mechanisms have been proposed as underlying specific placebo effects, and two that have particular relevance to hearing aid trials are conditioned learning and expectation (Thompson 2000) . A learned response is based on classical conditioning: if a person repeatedly experiences positive benefit with medical treatments, they may come to associate benefit with medical interventions generally. The unconditioned stimulus (the placebo treatment) becomes associated with a conditioned stimulus (e.g., penicillin and analgesics) that reliably relieves symptoms. More generally, subtle conditioning may be experienced through encounters with doctors, medicines, and other healing encounters. In terms of expectation, some placebo responses seem to be related to a strong expectation of benefit or expectation of a particular response to a treatment. For example, a group of pharmacology students received instruction on sedating and stimulating drugs (Blackwell et al. 1972) . They were then given placebo tablets; one blue pill or one pink pill, or two blue pills or two pink pills. Effects related to both the color of the pill and the dosage. Those who had taken blue pills experienced sedating effects, whereas those who had taken pink pills experienced stimulating ones. The interpretation was that the color of the pill had set up expectations about the sedating or stimulating nature of the pill. Students who had taken a higher "dose" of placebo pills experienced stronger effects, in line with the student's expectations.
Last, placebo effects are those clinical effects that are associated with the "symbolic import" of the treatment, rather than any intrinsic property of the treatment itself. Thus, placebo effects can occur in conjunction with active treatments and either facilitate or restrict them. For example, Luparello et al. (1968) administered either a bronchodilator or a brochnoconstrictor to four groups of asthmatic patients. Two groups were given accurate information about the treatment they received (i.e., those who received a bronchoconstrictor received a bronchoconstrictor or vise versa), whereas the other two groups were given misinformation (i.e., those who received a bronchoconstrictor actually received a bronchodilator or vise versa). For each treatment administered, expectation associated with misinformation about the treatment reduced its physiological effectiveness (by 49% for the bronchodilator and 43% for the bronchoconstrictor). "Nocebo effect" refers to cases where effectiveness of treatment is reduced by negative expectation (rather than being enhanced by positive ones, as in the case of the placebo effect).
Placebo Effects and Hearing Aid Trials
All the characteristics of placebos reviewed earlier might plausibly be relevant to hearing aid trials. First, placebo effects occur across a range of pharmacological, surgical, behavioral treatments, and trials of medical equipment. Placebo effects can occur in concert with and facilitate active treatments (or inhibit them, in the case of nocebo effects). They also occur in a sizable proportion of people. Effect sizes vary, and these encompass the effect sizes reported in clinical hearing aid trails (as discussed below). Second, placebo effects are "real" in a behavioral and physiological sense, and benefits are seen in specific physiological and behavioral measures. Although physiological measures are not typically used in hearing aid trials, one might expect placebo effects on a range of hearing aid benefit measures. Third, placebo effects could mirror exactly what the participant/client (and the clinician) expects in terms of hearing aid benefit and potentially have long-lasting effects. Fourth, clinician characteristics-sympathy, positive attitude, interest in the patient, and the clinician's own expectations of benefit-can influence the patient's response, and this may also impact both clinical trials and outcomes in a clinical setting. Fifth, placebo effects are highly specific, and this might be plausibly observed in hearing aid trials. For example, a benefit related to placebo effects might be seen for localization ability but not speech recognition, if it was expected that a particular hearing aid technology being evaluated would especially improve localization. Last, in terms of the mechanisms underlying placebo effects, both learned responses to use of medical devices and professional clinical attention as well as an expectation of benefit could plausibly affect hearing aid trial performance.
We are aware of only a single peer-reviewed study that has investigated the influence of expectation on measures of hearing aid benefit. Bentler et al. (2003) provided participants with two identical hearing aids that were labeled as either "conventional" or "digital." Hearing aids were used for 1 mo, and participants then completed a battery of hearing aid benefit measures including speech perception and self-report measures. Overall, the effect of labeling accounted for 2 to 32% of variance in outcome measures. Effects were generally small. With the exception of some subscales of the Abbreviated Profile of Hearing Aid Benefit (Cox & Alexander 1995) , differences in outcome measures were not significant individually. However, overall the authors concluded that the expectation that digital hearing aids must be better had affected their performance of measures of hearing aid benefit. Expectation that digital hearing aids must be better was further reflected by participant's choice of which hearing aid they preferred overall, with the statistically significant majority (33 of 40) stating that they preferred the digital aid.
To investigate patterns of benefit and how they vary according to study design, we compared the number of statistically significant treatment effects, and the size of effect, according to test type (subjective measures, such as benefit questionnaires and sound quality ratings, or behavioral measures, such as speech in noise tests) across a selection of hearing aid trials that used unblinded* (Ringdahl et al. 1990; Arlinger et al. 1998; Valente et al. 1998; Bamford et al. 1999;  *Unblinded studies are those in which both the participant and the experimenter are aware which is the experimental condition. Boymans et al. 1999; Ricketts & Dhar 1999) , single-blinded † (Bille et al. 1999; Boymans & Dreschler 2000; Wood & Lutman 2004) , or double-blinded ‡ (Hayes & Cormier 2000; Larson et al. 2002 ) methodology in comparing one type of hearing aid with another (i.e., aided A versus aided B performance). Note that the aforementioned studies were selected on the basis of a Google Scholar search with the key words "hearing aid trial," and on the availability of the full manuscript. Selection was thus not as rigorous as it should be for a reliable meta-analysis, and it is possible that the selection method may have introduced bias. However, the aim was to obtain a feel for general patterns of findings and how they might vary according to study design. The selection method resulted in a small selection of published hearing aid studies that are readily available to clinicians and researchers, and this seems a reasonable point from which to proceed.
Our first impression was that the majority of these hearing aid trials did not use double-blind methodology. Double-blind studies may be in the minority because of the extra expense and difficulty in conducting such studies. Until recently with the advent of programmable digital hearing aids, new hearing aids looked quite different from old ones and so were impossible use in blinded studies. In addition, the possible consequences of using unblinded study methodology may not be widely understood within the audiological community.
All these studies used a similar variety of outcome measures. All included a speech in noise task, and most included a self-report questionnaire about hearing aid benefit, sound quality ratings, or personal preference. In the discussion that follows, we draw a distinction between what we saw as two main categories of outcome measure: (1) speech in noise tests, which we refer to as "behavioral measures" and (2) questionnaires, sound quality ratings, and personal preference, which we refer to as "subjective measures." Behavioral measures are those that use psychophysical methodology and typically require participants to identify speech in background noise. Examples of this type of test included the Hearing in Noise test (Nilsson et al. 1994) and Four Alternative Auditory Feature test (FAAF; Foster & Haggard 1979) . Subjective measures are those that require the participant to make a judgment about their experience, typically using categorical or visual analog scale-based ratings. Examples of this type of measure included questionnaires (Abbreviated Profile of Hearing Aid Benefit; Cox & Alexander 1995) , Glasgow Hearing Aid Benefit Profile (Gatehouse 1999) , ratings of sound quality, or indicating a particular personal preference from a selection of alternative hearing aids.
For the unblinded studies cited earlier, five of six found a significant benefit for the "test" aid for behavioral measures (speech in noise tests), with effect sizes (r) ranging from 0.15 to 0.49. The mean effect size for behavioral measures was 0.25. Three of these studies included subjective sound quality ratings and all reported significant benefit. Likewise, three studies used self-report questionnaires and all found significant benefits for the "test" aid. For these measures, effect sizes varied widely from 0.1 to 0.99. Three studies also asked the participants for their overall personal preference and all found in favor of the "test" aid, with effect sizes ranging from 0.43 to 0.68. The mean effect size for subjective measures (sound quality ratings, self-report questionnaires, and personal preference) was 0.5.
For the three single-blind studies cited earlier, two studies found a significant benefit for both behavioral and self-report measures. Effect sizes could be calculated for only one of these studies where the necessary statistics were reported; 0.09 for the behavioral test (speech in noise, FAAF) and 0.45 for personal preference.
For the two double-blind studies, neither found any significant differences in performance on speech recognition tests. The study by Larson et al. (2002) found significant differences on ratings of sound quality (effect sizes 0.16 to 0.47) and self-report questionnaire (no statistics reported), whereas no significant differences were reported for the self-report questionnaire used in the study by Hayes and Cormier (2000) .
On the basis of this selection of studies, our overall impression is that unblinded hearing aid trials tend to find significant effects more frequently than double-blind trials. Significant differences seem to be more common for subjective measures than for behavioral ones. Where calculable, effect sizes were generally larger for unblinded versus blinded studies and for subjective measures versus behavioral ones.
In summary, in reviewing the characteristics of placebo effects and taking the findings of Bentler et al. (2003) study together with our brief survey of hearing aid trials, it is plausible that placebo effects may impact upon hearing aid clinical trials. If so, placebo effects would need to be taken into account when designing or interpreting hearing aid trials, and this would be an important consideration for all those involved with clinical hearing aid trials: hearing scientists, hearing aid manufacturers, hearing aid dispensers, and hearing aid users. We hypothesized that in a setting designed to reflect a scientific hearing aid trial, participants would perform better on a behavioral (speech and noise) test for a hearing aid described to them as containing new technology compared with an identical hearing aid described to them as being a conventional model. In addition, the "new" hearing aid would be rated more highly than the conventional one on sound quality judgments, and that the new aid would be preferred overall. Bentler et al. previously examined the effect of labeling hearing aids as digital and their findings suggested that participant expectation impacts upon hearing aid trials. However, it is not known whether these effects were specific to the digital label, with the study being carried out around the time when digital hearing aids were first being introduced, along with attendant marketing and associated excitement. In the present study, the intention was to examine whether the broader, less specific label of "new technology" would affect participant expectation in the same way that the digital label did in the study of Bentler et al.. If effects for the "new technology" label were found, then findings would be relevant for any hearing aid trial. Last, given that a general pattern in unblinded hearing aid trials was for larger effect sizes for subjective measures, we expected larger effect sizes for the two subjective measures (sound quality ratings and personal preference) compared with the speech in noise test. These hypotheses were examined as follows. † Single-blinded studies are those where the participant is unaware of the treatment condition, but the experimenter is aware of the condition. These studies offer partial control of the effects of expectation. Note that the expectations of the experimenter still have the potential to impact upon outcomes, see Gracely et al. (1985) . ‡ Double-blind studies are those where neither the participant nor the experimenter are aware which is the experimental condition and thus control for possible affects of expectation.
PARTICIPANTS AND METHODS

Participants
With the exception of the study by Larson et al.(2000) , all of the aforementioned hearing aid trials used small to medium sample sizes (N ϭ 12-50). Such sample sizes are sufficient to detect effects large enough to be of clinical relevance. In the present study, we were interested in detecting possible placebo effects, although these would not be of practical interest unless they were a similar size to the effects sought in hearing aid trials. We therefore selected a sample size of N ϭ 20 (13 males and 7 females) to provide similar statistical power to a typical hearing aid trial. Participants were recruited from a local hospital-based audiology clinic and ranged in age from 54 to 80 yr (M ϭ 69 yr, SD ϭ 6 yr). Inclusion criteria were (i) symmetrical mild to moderate, sloping high-frequency sensorineural hearing impairment (mean of Ն45 dB HL at 2-6 kHz), with Յ5 dB difference between the ears at two or more adjacent frequencies (between 0.25 and 8 kHz), (ii) normal middle ear function based on tympanometry, (iii) daily unilateral hearing aid use with minimum of 1 yr experience with a digital nonlinear behind-the-ear hearing aid, and (iv) English spoken as a first language. Pure-tone audiometry was carried out in a sound-treated room using a calibrated Kamplex KLD 21 audiometer, with TDH-39 headphones and B-71 bone vibrator. A GSI 38 Auto Tymp was used to assess middle ear function.
When invited to take part in the study, participants were sent an information sheet that stated that the purpose of the study was to evaluate new hearing aid technology. On completion of testing, they were informed of the true purpose of the study. Ethical approval was obtained from the relevant authorities and written consent was obtained from all participants. Participants had travel costs reimbursed. No other compensation was provided.
Test Hearing Aids
The hearing aids used were two Starkey A312 Strata behind-the-ear digital instruments with seven band, threechannel wide dynamic range compression with a noise reduction algorithm. The hearing aids had interchangeable yellow and beige covers. All participants used their current earmold (typically hard acrylic with pressure equalization vent) with the test hearing aids. Both test hearing aids were programmed to the same National Acoustic Laboratories' nonlinear fitting procedure (Version 1) prescription target based on a typical audiogram for age-related sensorineural hearing loss (35 dB HL at 500 Hz, 40 dB HL at 1 kHz, 50 dB HL at 2 kHz, 60 dB HL at 4 kHz, and 80 dB HL at 8 kHz). A typical audiogram was used (as opposed to each participant's individual audiogram) because this facilitated ease of testing and helped ensure that gain between hearing aids was equivalent (gain was measured several times before and after testing, as described in the following paragraphs). A close match to each individual's prescription target was unimportant, because the focus of this study was relative performance between new and conventional hearing aids, rather than absolute performance. The National Acoustic Laboratories' nonlinear fitting procedure (Version 1) real ear insertion-gain prescription target for these pure-tone thresholds is shown in the first line of Table 1 . After programming, three repeated coupler measures were made with each hearing aid using an Otometrics Aurical Plus testing system. The mean and standard deviation of these three measures are shown in Table 1 . The mean difference in gain § between the two test hearing aids was 3.1 dB (between 250 Hz and 4 kHz; maximum difference 3.4 dB at 4 kHz). Coupler measurements were also carried out after switching covers between the hearing aids and at the completion of testing to ensure a stable gain response. These measures are shown in Table 1 . Overall, differences between repeated coupler measures ranged between 0 and 3 dB, probably due to variation in test box position.
Subjective listening checks were carried out by three experienced hearing aid users. Bamford-Kowal-Bench (BKB) sentences (as described in later sections) were played over loudspeaker and out of the listener's view, the hearing aids were either switched or kept the same. After listening in both conditions, listeners were asked "Does this one sound the same or different to the other hearing aid?" No differences were reported.
In addition, casings were switched between the hearing aids so that for half the group, one hearing aid had a yellow case and was referred to as the new hearing aid while the other was the conventional aid with the beige case, whereas for the other half of the group, the casings and associated designations (conventional or new) were switched. This procedure was used to control for any actual differences that might exist between the two hearing aids.
Outcome Measures
For all measures, participants were seated 1.5 m from a loudspeaker at zero degrees azimuth. For all the auditory stimuli described below, sound levels refer to the level measured at the reference position, which was defined as the center of the participant's head with the participant absent. Daily § Mean difference in gain is the absolute difference in real ear insertion gain between hearing aids averaged across the test frequencies 250 Hz to 4 kHz. checks of calibration levels were carried out using a sound level meter.
Speech in Noise Test
The FAAF test (Foster & Haggard 1979 ; commercially available from the MRC Institute of Hearing Research in Nottingham,UK;http://www.ihr.mrc.ac.uk/index.php/products/ display/testmaterials) was used to assess aided speech perception in noise. The FAAF test is a computerized 80-item, single-syllable, closed-set word recognition test. Participants are asked to identify the key word embedded in the carrier phrase "Can you hear X clearly?" The participant then selects the perceived word via mouse click from four alternative responses displayed on the computer screen. The target word is presented along with three foils that differ from the target word by either one or two distinctive features. For example, the target word might be "lads" with the foils "land", "lad," and "lands". The FAAF test provides an overall percent correct score. The FAAF test was administered with test items at 65 dB (A) in speech-shaped noise at ϩ2 dB SNR at the reference position. This level of presentation was the same as that used in the hearing aid trial by Wood and Lutman (2004) , which also used the FAAF test. This presentation level allows for typical performance accuracy above 50% correct while remaining challenging enough to be below ceiling. The fixed speechshaped noise is designed to have the same long-term average spectrum as the test items. Before completing the FAAF test, participants familiarized themselves with the task by doing a short run of 12 FAAF test items. The FAAF test was performed with either the conventional or the new hearing aid first, with order of testing counter-balanced across participants.
Sound Quality Rating Test
To assess sound quality, a rating procedure was used based on that used by Arlinger et al. (1998) . Participants listened to six different sound samples (described in later sections) and rated them on three dimensions; clarity, comfort, and overall impression. The order of testing (i.e., new or conventional hearing aid first) was counter-balanced across participants. Ratings were awarded using a 10-point visual analog scale (e.g., for overall impression, "1" is "poor" and "10" is "excellent") similar to that used by Larson et al. (2000) . Participants were allowed to listen to each sample as many times as they liked before assigning a rating. Participants verbally provided a score to the examiner for each sample and each dimension. Sound samples were BKB sentences (Bench et al. 1979) ; for example, "The cat caught a mouse" or "The milk came in a bottle" spoken by male and female voices in quiet and in noise, music (excerpt from Beethoven's symphony number 1), and an environmental sound (robin song). All samples were approximately 10 sec long, digitized at 44 kHz, equalized to have the same long-term root mean square power, and presented at 65 dB (A). BKB sentences in noise were presented at ϩ2 dB SNR in broadband noise at the same overall presentation level for the sentences in isolation (65 dBA).
Personal Preference
At the end of the test session, participants were asked to state their overall personal preference using one of the three categories: "the new hearing aid is best," "the conventional hearing aid is best," or "I cannot tell any difference," as used by Arlinger et al. (1998) .
Procedure
At the start of the session, participants were given an explanation about the (false) aims of the study, that is, to evaluate some new hearing aid technology. Further questions from participants were anticipated at this point, such as "What is the new technology?", "How does the new technology improve hearing aid function?", and "What sort of benefit does the new technology provide?" Bogus responses to these questions were prepared, for example, in response to the question "What sort of benefits does the new hearing aid provide?", the tester was to answer that the new technology was thought to improve sound quality and speech recognition in noise. However, somewhat surprisingly, no participants had any questions about the trial at this point. Perhaps participants were simply willing to place their trust in the tester and comply with the requirements of testing.
After the (false) study explanation, participants were shown the two test hearing aids. The hearing aid with the yellow case was introduced to the participant as the "hearing aid with new technology." The reason given for the yellow case was that this was a prototype hearing aid. The hearing aid with the beige case was introduced as the "conventional hearing aid." Otoscopy, pure-tone audiometry, and tympanometry were then carried out, followed by the test protocol in the following order: FAAF test, sound quality ratings, and personal preference. Test sessions were approximately 1 h in duration.
RESULTS
After tests for normality, nonparametric measures for paired data were selected for FAAF test and sound quality ratings. FAAF data appeared to be nonnormally distributed because of two low-performing individuals. Performance was above chance levels for these individuals, and as relative differences in performance between two conditions (conventional versus new labels) rather than absolute performance is of interest in this study, data from these two individuals were retained and the appropriate nonparametric analysis applied.
FAAF Test
For the FAAF test, data from a single participant were excluded as responses were at chance level. It transpired that the participant was unable to read the response alternatives on the computer screen and had been guessing responses at random. For the remaining 19 participants, there was significantly better performance with the new hearing aid over the conventional aid, based on Wilcoxon signed-rank test (M ϭ 62.3%, SD ϭ 10.4 versus M ϭ 60.7%, SD ϭ 9.0; z ϭ Ϫ1.84, p ϭ 0.03, one-tailed, r ϭ 0.08). Using a more conservative two-tailed test, the difference was nonsignificant (p ϭ 0.06). Raw scores for the FAAF test are provided in Appendix A, Supplemental Digital Content 1 (http://links.lww.com/EANDH/A45).
Sound Quality Rating Test
Median score across the six different sound samples (described earlier) for each of the dimensions of comfort, clarity, and overall impression were obtained for each participant. Both hearing aids tended to be rated positively, although the new hearing aid was consistently rated more highly than the conventional one on the dimensions of clarity and overall impression, although the difference on comfort was nonsignificant (based on based on Wilcoxon signed-rank test). Overall sound quality rating (median of all subjective ratings) was significantly different between aids, with the new aid being rated more favorably. Mean ratings across participants and details of statistical comparisons are shown in Table 2 .
Personal Preference
Fifteen participants preferred the new hearing aid, while five could not tell the difference. None preferred the conventional aid. This difference was statistically significant [ 2 (1) ϭ 5.00, p ϭ 0.02, r ϭ 0.50].
DISCUSSION
The hypothesis that participants would perform better on tests of hearing aid benefit with a hearing aid described as containing new technology was supported. Significant differences in favor of the new hearing aid were seen on a speech in noise test and on ratings of sound quality and personal preference between two identical hearing aids that were described to participants as new and conventional. The inference is that describing one hearing aid as new, presenting it in the context of a hearing aid trial within an impressive setting (i.e., a University-based sound proof booth fitted with technical testing equipment) set up an expectation in participants that it must be better than a hearing aid labeled as conventional. This expectation then impacted upon participants' performance. For sound quality and personal preference, medium to large effect sizes observed. This finding was also consistent with our hypothesis that subjective measures (such as sound quality ratings and personal preference) would be more influenced by expectation than behavioral ones (such as the FAAF test). This finding is consistent with the pattern of results reported by Bentler et al. (2003) who found generally larger effects for subjective measures (hearing aid benefit questionnaire and personal preference) over behavioral ones (speech perception tasks) in research on the effect of labeling hearing aids as digital. If participant's expectation influences performance, then it seems reasonable that subjective measures that rely only on participant's self-report or opinion should be highly influenced by expectation. The FAAF test was perhaps less influenced because it uses psychophysical methodology with high test-retest reliability (Foster & Haggard, 1979) and is thus reasonably resistant to effects of expectation, presumably mediated by motivation or attention. Note that alternative speech tests using different stimuli and procedures may be more or less susceptible to the effect of expectation on performance depending on how susceptible they are to changes in participant motivation or attention. In this study, the size of the difference was small (r ϭ 0.08). With the hypothesis that the performance would be better with the new hearing aid (using a one-tailed probability criterion), the difference between conditions was significant. However, if one tested the hypothesis that performance with the new hearing aid may be either better or worse than the conventional one (using a two-tailed probability criterion), the difference was nonsignificant. If there is an effect of expectation on performance of speech in noise tests, then it is likely to be small and difficult to detect with small sample sizes. However, caution seems warranted for two reasons. First, the difference in FAAF performance was in the expected direction and the finding fits with the overall pattern of results showing better performance for the new aid. Thus, the performance difference, although small, may be real. Second, the size of the difference (ϳ2%) is not dissimilar to the small effects typically sought in some clinical hearing aid trials. For example, Valente et al. (1998) reported a statistically significant 1.6% improvement in performance in speech-in-noise in a trial of a digital hearing aid, and Wood and Lutman report similar size improvements (approximately 1-4%) in their 2004 trial. Compared with unaided performance, hearing aids provide a substantial benefit. Additional advances in hearing aid technology are generally not expected to increase performance greatly, so positive changes of a few percent in speech recognition may be satisfying to a hearing aid researcher. Placebo effects on speech in noise tests may be small, but in circumstances where small effects are of interest, they are significant.
The findings of the present study support the conclusion of Bentler et al. (2003) that participant expectation can affect performance on hearing aid outcome measures. The present study extends the work of Bentler et al. by suggesting that it is not just the digital label, but the more general label of new technology that can set up positive expectations about performance along with associated impact on outcome measures. This finding is relevant for any trial of new hearing aid technology.
This study sought to investigate the effect of participant expectation on tests of hearing aid benefit by imitating the design of a typical uncontrolled hearing aid trial. This study differs from an actual uncontrolled hearing aid trial in one potentially important respect, however. In an actual uncontrolled hearing aid trial, both the participant and the (hopeful) experimenter would likely have an expectation that the new hearing aid would perform better than the conventional one. In the present study, although participants may have had an expectation of better performance from the new hearing aid, the experimenter was aware that the aids were in fact identical. Research reviewed in the Introduction section (Gracely et al. 1985) suggests that the expectation of the experimenter can subtly impact upon participants' expectations. Therefore in the case of the present study, the experimenter's expectations may have encouraged a tendency toward null findings. Placebo effects in actual uncontrolled hearing aid trials may, in fact, be larger than those reported in this study. Alternatively, given that our hypothesis was that there would be differences between the hearing aids, the experimenter's expectation of difference may have had the opposite effect, that is, to encourage a bias in favor of the new hearing aid. Disentangling the effects of participant and experimenter expectations on outcome would require deception of both the participant and the person collecting the data (i.e., so that the data collector also believed this was a real trial of new hearing aid technology), and this was not possible in the present study.
Another limitation of the present study is that because of time and ethical constraints, only immediate outcome measures were used. Thus, the duration of the effects observed in this study is unclear. However, Bentler et al. (2003) found that the influence of labeling a hearing aid as digital persisted after 4 wk of hearing aid use. In addition, research on placebo effects reviewed in the Introduction section found that, depending on circumstances surrounding the treatment, placebo effects could be very long lasting, up to a year in the case of sham surgery for heart problems (Dimons et al. 1960) . It is possible, therefore, that the affects of labeling and expectation on hearing aid benefit may be long lasting, and this is a topic for future research (see the later section on the role of placebo effects in audiological clinical practice). A final limitation of the present study is that the use of experienced hearing aid users may limit the generalizability of findings to hearing aid trials that also use experienced hearing aid users. Some technologies are trialed with normal-hearing participants under conditions that simulate hearing loss. It is possible that the same sort of mechanism associated with the expectations surrounding the technology, as posited in this article, may apply. This is also an area for future enquiry.
The findings of the present study support the conclusion of Bentler et al.(2003) that participant expectation can affect performance on hearing aid outcome measures. The present study extends the work of Bentler et al. by suggesting that it is not just the digital label but also the broader label of new technology that can set up positive expectations about performance along with associated impact on outcome measures, and this is relevant for any trial of new hearing aid technology. One of the general conclusions of this study, then, is that placebo effects need to be controlled to have confidence in the results of clinical hearing aid trials, ideally by using double-blind methodology in a randomized controlled study. However, the majority of hearing aid trials do not use double-blind designs, perhaps due to practical limitations. For example, the new device may look physically different from the conventional one, or because financial or staffing limitations preclude conducting a more elaborate double-blind study design. How should hearing aid trials that do not use double-blind designs be interpreted? Or, stated another way, do studies that do not use double-blind designs provide reliable data? Glasziou et al. (2007) discussed this issue in relation to clinical medical trials. They concluded that in circumstances where the treatment effect was so large that is was unlikely to be a reflection of bias or factors other than treatment effect, it may be permissible to rely on an uncontrolled study design. Glasziou et al. provide examples where the treatment effect was around 10 times the size of the expected outcome based on the usual natural progression of the condition under examination. This principle is potentially applicable to clinical hearing aid trials. However, the difficulty seems to lie in determining how large an effect could be attributable to treatment. Literature reviewed in the Introduction section suggests that the effect size attributable to placebo effects is variable according to various design factors. In any case, very large effects are not normally observed in trials of new hearing aid technology, at least with psychophysical outcome measures. The small effect sizes that are typically sought are comparable in size to those observed in this study, which were due to expectation alone. An alternative strategy to control for placebo effects without the use of a double-blind methodology might be to include outcome measures that are not expected to change with the new treatment along with some that were expected to change. Specific changes in particular outcome measures might then be taken as evidence for a real treatment effect. However, as reviewed in the Introduction section, placebo effects can be highly specific and may mimic the pattern of findings expected by researchers and participants. This strategy is thus also potentially open to placebo effects and is not a reliable research design. A second alternative could be to use single-blind methodology. Single-blind hearing aid trials are preferable to unblinded trials because they do control for the effects of participant expectation. However, expectations of the researcher may still potentially affect results (Gracely et al. 1985) . In summary, there do not appear to be any good alternatives to the gold standard double-blind randomized controlled study design if one wishes to rigorously control for placebo effects. Other types of study design should be used (and the findings thereof interpreted) with caution.
The focus of this study was participant expectation in the context of clinical hearing aid trials where one hearing aid is being compared against another. One might expect participant expectations to influence satisfaction, benefit, and compliance in a clinical setting as well as a research one, and this may be a productive area of future research. Research reviewed in the Introduction section also suggests that placebo effects occur widely across populations, clinical conditions, and treatments. Conclusions of this study may then be relevant to other areas of audiology. Researchers and clinicians may benefit from an awareness of possible placebo effects in other audiological populations and conditions, such as tinnitus or hyperacusis.
Last, and perhaps most controversial, is that, there is a potential role of placebo effects in clinical audiology. Reviews of the placebo effect in relation to clinical medicine, cited earlier in this earlier (Turner et al. 1994; Thompson 2000; Price et al. 2008) , suggest that placebo effects could be (and are) ethically used to optimize the outcome for patients. Such effects might be fostered by use of suggestion or via positive interactions between the clinician and the patient. In audiology, this could, for example, take the form of emphasizing the empirically proven benefits of hearing aids to a new hearing aid user during an initial fitting. This, combined with a warm, confident and professional attitude on the part of the clinician could result in greater benefit and compliance on the part of the hearing aid user. Of course, this is a matter for careful research in verifying and quantifying such potential benefits and for informed debate among audiologists and professional bodies as to how placebo effects might ethically be used in clinical practice. In any case, placebo effects and the manipulation of expectation potentially offer an additional tool to maximize real benefit for audiology patients.
CONCLUSIONS
In this study, measures typical of those used in clinical hearing aid trials were influenced by participant's expectations. This study suggests that there is a need to control for placebo effects in hearing aid trials and for caution in interpreting findings from trials that did not include such controls.
